Association Between Vitamin D Status and Risk of Developing Severe COVID-19 Infection: A Meta-Analysis of Observational Studies
Overview
Affiliations
Objective: The relationship between 25-hydroxyvitamin D3 (25(OH)D), the surrogate marker for vitamin D, serum concentration and COVID-19 has come to the forefront as a potential pathway to improve COVID-19 outcomes. The current evidence remains unclear on the impact of vitamin D status on the severity and outcomes of COVID-19 infection. To explore possible association between low 25(OH)D levels and risk of developing severe COVID-19 (i.e. need for invasive mechanical ventilation, the length of hospital stay, total deaths). We also aimed to understand the relationship between vitamin D insufficiency and elevated inflammatory and cardiac biomarkers.
Methods: We conducted a comprehensive electronic literature search for any original research study published up to March 30, 2021. For the purpose of this review, low vitamin D status was defined as a range of serum total 25(OH)D levels of <10 to <30 ng/ml. Two independent investigators assessed study eligibility, synthesized evidence, analyzed, critically examined, and interpreted herein.
Results: Twenty-four observational studies containing 3637 participants were included in the meta-analysis. The mean age of the patients was 61.1 years old; 56% were male. Low vitamin D status was statistically associated with higher risk of death (RR, 1.60 (95% CI, 1.10-2.32), higher risk of developing severe COVID-19 pneumonia (RR: 1.50; 95% CI, 1.10-2.05). COVID-19 patients with low vitamin D levels had a greater prevalence of hypertension and cardiovascular diseases, abnormally high serum troponin and peak D-dimer levels, as well as elevated interleukin-6 and C-reactive protein than those with serum 25(OH)D levels ≥30 ng/ml.
Conclusions: In this meta-analysis, we found a potential increased risk of developing severe COVID-19 infection among patients with low vitamin D levels. There are plausible biological mechanisms supporting the role of vitamin D in COVID-19 severity. Randomized controlled trials are needed to test for potential beneficial effects of vitamin D in COVID-19 outcomes.
Wimalawansa S Nutrients. 2025; 17(3).
PMID: 39940457 PMC: 11820523. DOI: 10.3390/nu17030599.
Atieh O, Daher J, Durieux J, Abboud M, Labbato D, Baissary J Nutrients. 2025; 17(2).
PMID: 39861434 PMC: 11767688. DOI: 10.3390/nu17020304.
Simon-Frapolli V, Lopez-Montalban A, Vegas-Aguilar I, Generoso-Pinar M, Fernandez-Jimenez R, Cornejo-Pareja I Nutrients. 2025; 17(1.
PMID: 39796549 PMC: 11722648. DOI: 10.3390/nu17010110.
Impact of vitamin D on COVID-19 and other viral diseases.
Nagoba B, Gavkare A, Rayate A, Nanaware N, Bhavthankar S World J Virol. 2024; 13(4):100356.
PMID: 39722759 PMC: 11551689. DOI: 10.5501/wjv.v13.i4.100356.
Wimalawansa S Biology (Basel). 2024; 13(10).
PMID: 39452140 PMC: 11504239. DOI: 10.3390/biology13100831.